| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Homosexuality, Male | 189 | 2024 | 486 | 38.640 |
Why?
|
| Bisexuality | 122 | 2020 | 211 | 30.090 |
Why?
|
| Sexual Behavior | 116 | 2023 | 638 | 17.610 |
Why?
|
| HIV Infections | 165 | 2024 | 2586 | 15.830 |
Why?
|
| Sexual Partners | 85 | 2020 | 326 | 14.190 |
Why?
|
| Risk-Taking | 95 | 2020 | 457 | 12.060 |
Why?
|
| Unsafe Sex | 66 | 2018 | 162 | 11.800 |
Why?
|
| Substance-Related Disorders | 84 | 2021 | 830 | 10.350 |
Why?
|
| HIV Seropositivity | 56 | 2018 | 196 | 8.560 |
Why?
|
| Compulsive Behavior | 24 | 2023 | 31 | 6.670 |
Why?
|
| Condoms | 38 | 2020 | 150 | 6.140 |
Why?
|
| Adult | 226 | 2024 | 13872 | 5.590 |
Why?
|
| Male | 277 | 2024 | 23409 | 5.260 |
Why?
|
| New York City | 82 | 2019 | 288 | 5.130 |
Why?
|
| Young Adult | 126 | 2024 | 5080 | 4.790 |
Why?
|
| Internet | 26 | 2016 | 236 | 4.250 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2019 | 497 | 3.980 |
Why?
|
| Humans | 292 | 2024 | 43102 | 3.940 |
Why?
|
| Adolescent | 119 | 2024 | 6081 | 3.520 |
Why?
|
| Middle Aged | 126 | 2019 | 12222 | 3.490 |
Why?
|
| Drug Users | 13 | 2019 | 52 | 3.410 |
Why?
|
| Anti-HIV Agents | 21 | 2021 | 486 | 3.260 |
Why?
|
| Risk Reduction Behavior | 18 | 2019 | 138 | 3.230 |
Why?
|
| Medication Adherence | 17 | 2021 | 182 | 3.130 |
Why?
|
| Safe Sex | 26 | 2019 | 78 | 3.040 |
Why?
|
| Alcohol Drinking | 20 | 2020 | 609 | 2.850 |
Why?
|
| Depression | 23 | 2019 | 863 | 2.770 |
Why?
|
| Motivation | 30 | 2019 | 513 | 2.720 |
Why?
|
| Mental Health | 16 | 2017 | 385 | 2.520 |
Why?
|
| Stress, Psychological | 12 | 2017 | 661 | 2.230 |
Why?
|
| Social Support | 15 | 2017 | 445 | 2.110 |
Why?
|
| HIV Seronegativity | 10 | 2019 | 41 | 2.070 |
Why?
|
| Counseling | 5 | 2019 | 138 | 2.050 |
Why?
|
| Sexually Transmitted Diseases | 14 | 2018 | 174 | 2.040 |
Why?
|
| Patient Compliance | 14 | 2017 | 233 | 2.030 |
Why?
|
| Attitude to Health | 14 | 2015 | 338 | 2.010 |
Why?
|
| Amphetamine-Related Disorders | 7 | 2018 | 69 | 2.010 |
Why?
|
| Methamphetamine | 10 | 2018 | 166 | 1.920 |
Why?
|
| Central Nervous System Stimulants | 10 | 2018 | 180 | 1.830 |
Why?
|
| Health Knowledge, Attitudes, Practice | 23 | 2019 | 989 | 1.800 |
Why?
|
| Self Disclosure | 9 | 2017 | 44 | 1.800 |
Why?
|
| Sexual Dysfunctions, Psychological | 4 | 2023 | 13 | 1.780 |
Why?
|
| Homosexuality | 8 | 2016 | 36 | 1.710 |
Why?
|
| Homosexuality, Female | 7 | 2012 | 60 | 1.690 |
Why?
|
| Interpersonal Relations | 16 | 2017 | 222 | 1.660 |
Why?
|
| Female | 97 | 2024 | 24698 | 1.610 |
Why?
|
| Self Concept | 6 | 2019 | 171 | 1.560 |
Why?
|
| Emotions | 7 | 2018 | 254 | 1.530 |
Why?
|
| Communication | 6 | 2019 | 210 | 1.510 |
Why?
|
| Anti-Retroviral Agents | 9 | 2021 | 160 | 1.490 |
Why?
|
| Stereotyping | 6 | 2013 | 45 | 1.480 |
Why?
|
| Social Behavior | 10 | 2015 | 161 | 1.460 |
Why?
|
| United States | 41 | 2024 | 5205 | 1.460 |
Why?
|
| Viral Load | 15 | 2021 | 348 | 1.430 |
Why?
|
| Patient Selection | 7 | 2018 | 205 | 1.430 |
Why?
|
| Urban Population | 14 | 2016 | 374 | 1.420 |
Why?
|
| Aged | 45 | 2020 | 8214 | 1.400 |
Why?
|
| Mass Screening | 9 | 2019 | 541 | 1.380 |
Why?
|
| Socioeconomic Factors | 20 | 2016 | 1234 | 1.360 |
Why?
|
| Health Behavior | 10 | 2020 | 575 | 1.290 |
Why?
|
| Self Efficacy | 15 | 2021 | 215 | 1.280 |
Why?
|
| Prevalence | 23 | 2021 | 1612 | 1.270 |
Why?
|
| Cross-Sectional Studies | 36 | 2018 | 3156 | 1.250 |
Why?
|
| Psychometrics | 8 | 2018 | 358 | 1.250 |
Why?
|
| Prescription Drugs | 3 | 2015 | 32 | 1.180 |
Why?
|
| Longitudinal Studies | 14 | 2019 | 1063 | 1.180 |
Why?
|
| Family Characteristics | 8 | 2019 | 126 | 1.170 |
Why?
|
| Child Abuse, Sexual | 4 | 2018 | 22 | 1.170 |
Why?
|
| Risk Factors | 31 | 2018 | 3994 | 1.160 |
Why?
|
| Minority Groups | 7 | 2017 | 690 | 1.130 |
Why?
|
| Health Surveys | 15 | 2018 | 405 | 1.130 |
Why?
|
| Decision Making | 4 | 2019 | 249 | 1.100 |
Why?
|
| Erotica | 2 | 2018 | 3 | 1.100 |
Why?
|
| Men | 4 | 2017 | 19 | 1.100 |
Why?
|
| Interviews as Topic | 15 | 2019 | 452 | 1.090 |
Why?
|
| Social Identification | 5 | 2014 | 65 | 1.060 |
Why?
|
| Data Collection | 14 | 2015 | 210 | 1.050 |
Why?
|
| Marijuana Smoking | 3 | 2019 | 91 | 1.040 |
Why?
|
| Alcoholism | 8 | 2014 | 305 | 1.040 |
Why?
|
| Personal Satisfaction | 7 | 2019 | 76 | 1.040 |
Why?
|
| Anxiety | 10 | 2019 | 874 | 1.010 |
Why?
|
| Behavior Therapy | 7 | 2010 | 180 | 1.010 |
Why?
|
| Gender Identity | 5 | 2017 | 117 | 0.980 |
Why?
|
| Spirituality | 2 | 2017 | 53 | 0.970 |
Why?
|
| Leisure Activities | 3 | 2011 | 41 | 0.960 |
Why?
|
| Object Attachment | 3 | 2019 | 28 | 0.950 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2019 | 201 | 0.940 |
Why?
|
| Cocaine-Related Disorders | 6 | 2014 | 102 | 0.910 |
Why?
|
| Drug Monitoring | 4 | 2020 | 69 | 0.900 |
Why?
|
| Alcohol-Related Disorders | 3 | 2012 | 63 | 0.900 |
Why?
|
| Executive Function | 2 | 2018 | 59 | 0.880 |
Why?
|
| Truth Disclosure | 6 | 2012 | 26 | 0.840 |
Why?
|
| Logistic Models | 15 | 2017 | 1009 | 0.840 |
Why?
|
| Models, Psychological | 6 | 2017 | 140 | 0.830 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2010 | 229 | 0.820 |
Why?
|
| Research Personnel | 3 | 2016 | 206 | 0.800 |
Why?
|
| Disease Transmission, Infectious | 2 | 2015 | 30 | 0.770 |
Why?
|
| Affect | 3 | 2015 | 180 | 0.770 |
Why?
|
| Pilot Projects | 12 | 2019 | 760 | 0.770 |
Why?
|
| Social Environment | 6 | 2014 | 218 | 0.760 |
Why?
|
| Health Promotion | 7 | 2018 | 704 | 0.760 |
Why?
|
| Hypnotics and Sedatives | 4 | 2015 | 27 | 0.720 |
Why?
|
| Personality Inventory | 4 | 2015 | 82 | 0.720 |
Why?
|
| Transsexualism | 3 | 2011 | 20 | 0.720 |
Why?
|
| Intention | 3 | 2018 | 108 | 0.710 |
Why?
|
| Telemedicine | 4 | 2019 | 234 | 0.690 |
Why?
|
| AIDS Serodiagnosis | 5 | 2017 | 25 | 0.690 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 638 | 0.690 |
Why?
|
| Psychology | 3 | 2019 | 39 | 0.690 |
Why?
|
| Health Education | 5 | 2012 | 363 | 0.670 |
Why?
|
| Primary Prevention | 3 | 2016 | 63 | 0.670 |
Why?
|
| Comorbidity | 8 | 2019 | 737 | 0.630 |
Why?
|
| Age Factors | 13 | 2019 | 1154 | 0.620 |
Why?
|
| Video Recording | 1 | 2019 | 41 | 0.610 |
Why?
|
| Home Care Services | 2 | 2017 | 37 | 0.610 |
Why?
|
| Patient Preference | 2 | 2018 | 60 | 0.610 |
Why?
|
| Serologic Tests | 1 | 2019 | 45 | 0.600 |
Why?
|
| Factor Analysis, Statistical | 6 | 2014 | 162 | 0.600 |
Why?
|
| Depressive Disorder | 3 | 2017 | 187 | 0.590 |
Why?
|
| Mental Disorders | 2 | 2015 | 392 | 0.590 |
Why?
|
| Military Personnel | 1 | 2020 | 110 | 0.590 |
Why?
|
| Program Evaluation | 5 | 2019 | 359 | 0.580 |
Why?
|
| Residence Characteristics | 3 | 2016 | 363 | 0.580 |
Why?
|
| Religion | 2 | 2017 | 90 | 0.580 |
Why?
|
| Qualitative Research | 8 | 2019 | 574 | 0.560 |
Why?
|
| Cognition | 3 | 2021 | 473 | 0.550 |
Why?
|
| HIV-1 | 3 | 2010 | 755 | 0.550 |
Why?
|
| Harm Reduction | 4 | 2007 | 27 | 0.540 |
Why?
|
| Prospective Studies | 6 | 2018 | 1600 | 0.540 |
Why?
|
| Human Development | 1 | 2017 | 9 | 0.540 |
Why?
|
| Population Density | 1 | 2017 | 38 | 0.530 |
Why?
|
| San Francisco | 14 | 2006 | 35 | 0.530 |
Why?
|
| Religion and Sex | 1 | 2017 | 2 | 0.520 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 1081 | 0.510 |
Why?
|
| Psychomotor Performance | 1 | 2018 | 159 | 0.510 |
Why?
|
| Follow-Up Studies | 9 | 2015 | 1067 | 0.500 |
Why?
|
| Brazil | 4 | 2019 | 84 | 0.500 |
Why?
|
| Urethral Diseases | 1 | 2016 | 1 | 0.490 |
Why?
|
| Rectal Diseases | 1 | 2016 | 4 | 0.490 |
Why?
|
| Treatment Outcome | 12 | 2015 | 1604 | 0.490 |
Why?
|
| Sex Factors | 10 | 2016 | 1028 | 0.480 |
Why?
|
| Gonorrhea | 1 | 2016 | 24 | 0.470 |
Why?
|
| Crime Victims | 1 | 2016 | 77 | 0.470 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 15 | 0.460 |
Why?
|
| Men's Health | 2 | 2012 | 13 | 0.450 |
Why?
|
| Sex Education | 4 | 2014 | 36 | 0.450 |
Why?
|
| Perception | 6 | 2018 | 215 | 0.440 |
Why?
|
| Chlamydia Infections | 2 | 2018 | 200 | 0.440 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2853 | 0.440 |
Why?
|
| Self Care | 2 | 2013 | 175 | 0.430 |
Why?
|
| Disclosure | 2 | 2004 | 39 | 0.430 |
Why?
|
| Penis | 2 | 2012 | 90 | 0.420 |
Why?
|
| Voluntary Programs | 1 | 2014 | 4 | 0.420 |
Why?
|
| Culture | 5 | 2014 | 172 | 0.420 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2005 | 129 | 0.410 |
Why?
|
| Group Processes | 1 | 2013 | 23 | 0.400 |
Why?
|
| Heterosexuality | 1 | 2014 | 97 | 0.400 |
Why?
|
| New York | 7 | 2013 | 93 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2018 | 226 | 0.390 |
Why?
|
| Preventive Health Services | 1 | 2013 | 66 | 0.390 |
Why?
|
| Cohort Studies | 5 | 2018 | 1759 | 0.390 |
Why?
|
| Antisocial Personality Disorder | 1 | 2013 | 20 | 0.390 |
Why?
|
| Patient Education as Topic | 5 | 2019 | 235 | 0.390 |
Why?
|
| Love | 1 | 2012 | 6 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 749 | 0.380 |
Why?
|
| Quality of Life | 1 | 2017 | 616 | 0.370 |
Why?
|
| Adult Survivors of Child Abuse | 3 | 2018 | 26 | 0.370 |
Why?
|
| Femininity | 1 | 2012 | 5 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 375 | 0.360 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 420 | 0.360 |
Why?
|
| Masculinity | 1 | 2012 | 19 | 0.360 |
Why?
|
| Hobbies | 1 | 2011 | 2 | 0.350 |
Why?
|
| Program Development | 4 | 2016 | 240 | 0.340 |
Why?
|
| Negotiating | 4 | 2016 | 27 | 0.340 |
Why?
|
| Health Status Disparities | 2 | 2017 | 719 | 0.340 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 590 | 0.340 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 706 | 0.340 |
Why?
|
| Science | 1 | 2011 | 24 | 0.340 |
Why?
|
| Risk Management | 1 | 2010 | 8 | 0.330 |
Why?
|
| Sampling Studies | 3 | 2016 | 64 | 0.330 |
Why?
|
| Time Factors | 6 | 2015 | 1857 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 282 | 0.330 |
Why?
|
| Religion and Psychology | 1 | 2010 | 27 | 0.320 |
Why?
|
| Models, Theoretical | 4 | 2017 | 232 | 0.320 |
Why?
|
| Sexuality | 2 | 2011 | 56 | 0.320 |
Why?
|
| Los Angeles | 6 | 2018 | 394 | 0.320 |
Why?
|
| Alcoholic Intoxication | 1 | 2010 | 21 | 0.320 |
Why?
|
| Regression Analysis | 6 | 2018 | 490 | 0.310 |
Why?
|
| Syphilis | 1 | 2009 | 24 | 0.310 |
Why?
|
| Psychotherapy, Group | 1 | 2009 | 23 | 0.300 |
Why?
|
| Interview, Psychological | 1 | 2009 | 63 | 0.300 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2009 | 53 | 0.300 |
Why?
|
| Computer-Assisted Instruction | 1 | 2009 | 26 | 0.300 |
Why?
|
| Focus Groups | 6 | 2016 | 423 | 0.300 |
Why?
|
| Smoking | 3 | 2012 | 1024 | 0.300 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 2019 | 7 | 0.300 |
Why?
|
| Analysis of Variance | 4 | 2014 | 575 | 0.290 |
Why?
|
| Feasibility Studies | 6 | 2019 | 259 | 0.280 |
Why?
|
| Research Design | 5 | 2018 | 385 | 0.280 |
Why?
|
| Family | 1 | 2009 | 195 | 0.280 |
Why?
|
| Clinical Competence | 1 | 2009 | 156 | 0.280 |
Why?
|
| Awareness | 2 | 2018 | 73 | 0.270 |
Why?
|
| Psychotherapy | 2 | 2023 | 59 | 0.260 |
Why?
|
| Risk Assessment | 8 | 2018 | 863 | 0.260 |
Why?
|
| Drug Prescriptions | 2 | 2007 | 60 | 0.260 |
Why?
|
| Sleep | 2 | 2019 | 185 | 0.250 |
Why?
|
| Thailand | 5 | 2014 | 51 | 0.250 |
Why?
|
| Spouse Abuse | 1 | 2007 | 52 | 0.250 |
Why?
|
| Life Change Events | 1 | 2007 | 109 | 0.240 |
Why?
|
| Needs Assessment | 1 | 2007 | 178 | 0.230 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2012 | 568 | 0.220 |
Why?
|
| Impulsive Behavior | 2 | 2016 | 55 | 0.220 |
Why?
|
| Loneliness | 2 | 2019 | 24 | 0.220 |
Why?
|
| Health Personnel | 2 | 2018 | 277 | 0.220 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 236 | 0.220 |
Why?
|
| Lysergic Acid Diethylamide | 3 | 2009 | 4 | 0.220 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2009 | 8 | 0.220 |
Why?
|
| Ketamine | 3 | 2009 | 13 | 0.210 |
Why?
|
| Body Image | 2 | 2017 | 89 | 0.210 |
Why?
|
| Prejudice | 3 | 2012 | 116 | 0.210 |
Why?
|
| Demography | 3 | 2009 | 195 | 0.200 |
Why?
|
| Life Style | 1 | 2006 | 334 | 0.200 |
Why?
|
| Terrorism | 1 | 2003 | 13 | 0.200 |
Why?
|
| HIV Protease Inhibitors | 1 | 2003 | 24 | 0.200 |
Why?
|
| Social Class | 2 | 2016 | 291 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2014 | 195 | 0.180 |
Why?
|
| Health Status | 5 | 2017 | 442 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2014 | 587 | 0.180 |
Why?
|
| Antiviral Agents | 2 | 2016 | 195 | 0.170 |
Why?
|
| Adolescent Behavior | 5 | 2016 | 281 | 0.170 |
Why?
|
| Child | 5 | 2023 | 3443 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 68 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2544 | 0.160 |
Why?
|
| Injections | 2 | 2018 | 42 | 0.160 |
Why?
|
| HIV Long-Term Survivors | 2 | 2010 | 7 | 0.160 |
Why?
|
| Space-Time Clustering | 2 | 2009 | 3 | 0.150 |
Why?
|
| Contact Tracing | 1 | 2019 | 25 | 0.150 |
Why?
|
| Social Perception | 3 | 2013 | 72 | 0.150 |
Why?
|
| Hallucinogens | 2 | 2009 | 29 | 0.150 |
Why?
|
| Sex Characteristics | 2 | 2012 | 258 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 24 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 51 | 0.140 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 252 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2018 | 45 | 0.140 |
Why?
|
| HIV | 1 | 2018 | 100 | 0.140 |
Why?
|
| Sodium Oxybate | 2 | 2009 | 3 | 0.140 |
Why?
|
| Shame | 1 | 2018 | 6 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2019 | 142 | 0.140 |
Why?
|
| Choice Behavior | 3 | 2007 | 93 | 0.140 |
Why?
|
| Defense Mechanisms | 1 | 2017 | 10 | 0.140 |
Why?
|
| Probability | 1 | 2018 | 82 | 0.140 |
Why?
|
| Fatigue | 1 | 2018 | 100 | 0.140 |
Why?
|
| Puberty | 1 | 2017 | 31 | 0.130 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 165 | 0.130 |
Why?
|
| Risk | 2 | 2016 | 287 | 0.130 |
Why?
|
| Minority Health | 1 | 2017 | 95 | 0.120 |
Why?
|
| Multilevel Analysis | 1 | 2015 | 21 | 0.120 |
Why?
|
| Language | 2 | 2014 | 185 | 0.120 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 92 | 0.110 |
Why?
|
| Cultural Characteristics | 2 | 2012 | 128 | 0.110 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 116 | 0.110 |
Why?
|
| Analgesics | 1 | 2015 | 55 | 0.110 |
Why?
|
| Translating | 1 | 2014 | 18 | 0.110 |
Why?
|
| Social Facilitation | 1 | 2014 | 6 | 0.110 |
Why?
|
| Sex Offenses | 1 | 2015 | 45 | 0.110 |
Why?
|
| Personality Disorders | 1 | 2014 | 21 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 440 | 0.110 |
Why?
|
| Domestic Violence | 1 | 2014 | 32 | 0.110 |
Why?
|
| Uncertainty | 2 | 2011 | 32 | 0.110 |
Why?
|
| Linear Models | 2 | 2013 | 317 | 0.110 |
Why?
|
| Organ Size | 2 | 2012 | 170 | 0.110 |
Why?
|
| Social Responsibility | 2 | 2004 | 16 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 231 | 0.110 |
Why?
|
| Personality | 1 | 2014 | 55 | 0.110 |
Why?
|
| Rural Population | 1 | 2017 | 373 | 0.100 |
Why?
|
| Random Allocation | 1 | 2014 | 147 | 0.100 |
Why?
|
| Incidence | 2 | 2010 | 1078 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cluster Analysis | 2 | 2013 | 207 | 0.100 |
Why?
|
| Utilization Review | 1 | 2013 | 17 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2013 | 24 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 104 | 0.100 |
Why?
|
| Psychotropic Drugs | 1 | 2013 | 18 | 0.100 |
Why?
|
| Urban Health | 1 | 2013 | 101 | 0.100 |
Why?
|
| Psychopathology | 1 | 2013 | 20 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2013 | 44 | 0.100 |
Why?
|
| Jealousy | 1 | 2012 | 2 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 67 | 0.100 |
Why?
|
| Caffeine | 1 | 2012 | 28 | 0.090 |
Why?
|
| Marijuana Abuse | 1 | 2014 | 100 | 0.090 |
Why?
|
| Cannabinoids | 1 | 2013 | 73 | 0.090 |
Why?
|
| Internal-External Control | 2 | 2009 | 63 | 0.090 |
Why?
|
| Educational Status | 1 | 2013 | 339 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 55 | 0.090 |
Why?
|
| Psychological Tests | 2 | 2013 | 56 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 719 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 284 | 0.090 |
Why?
|
| Observation | 1 | 2011 | 10 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 291 | 0.080 |
Why?
|
| Primary Health Care | 2 | 2017 | 380 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 218 | 0.080 |
Why?
|
| New Jersey | 1 | 2010 | 15 | 0.080 |
Why?
|
| Psychological Theory | 2 | 2009 | 26 | 0.080 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2009 | 1 | 0.080 |
Why?
|
| Birds | 1 | 2011 | 96 | 0.080 |
Why?
|
| Recreation | 1 | 2010 | 43 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2009 | 44 | 0.080 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2009 | 92 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 704 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 123 | 0.080 |
Why?
|
| Inservice Training | 1 | 2009 | 33 | 0.070 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 8 | 0.070 |
Why?
|
| Social Isolation | 2 | 2010 | 34 | 0.070 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2009 | 83 | 0.070 |
Why?
|
| Public Health | 1 | 2013 | 424 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 173 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 60 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 25 | 0.070 |
Why?
|
| Anecdotes as Topic | 2 | 2008 | 6 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2009 | 224 | 0.070 |
Why?
|
| Fear | 2 | 2015 | 272 | 0.070 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 219 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2012 | 1546 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 968 | 0.070 |
Why?
|
| Citalopram | 1 | 2006 | 3 | 0.060 |
Why?
|
| Health Literacy | 1 | 2009 | 130 | 0.060 |
Why?
|
| Goals | 1 | 2007 | 34 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 259 | 0.060 |
Why?
|
| Cocaine | 1 | 2009 | 251 | 0.060 |
Why?
|
| Peer Group | 2 | 2005 | 177 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 32 | 0.060 |
Why?
|
| Breast Self-Examination | 1 | 2006 | 13 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2006 | 18 | 0.060 |
Why?
|
| Ejaculation | 1 | 2005 | 11 | 0.060 |
Why?
|
| Women's Health | 1 | 2006 | 160 | 0.060 |
Why?
|
| Piperazines | 1 | 2005 | 120 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 368 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 712 | 0.050 |
Why?
|
| Self Administration | 1 | 2003 | 69 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2003 | 154 | 0.050 |
Why?
|
| Telephone | 1 | 2020 | 36 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 12 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 120 | 0.040 |
Why?
|
| Chlamydia | 1 | 2018 | 45 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 70 | 0.030 |
Why?
|
| Animals | 2 | 2013 | 16992 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 260 | 0.030 |
Why?
|
| Texas | 1 | 2018 | 457 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 29 | 0.030 |
Why?
|
| Social Conditions | 1 | 2015 | 13 | 0.030 |
Why?
|
| California | 2 | 2010 | 548 | 0.030 |
Why?
|
| Anthropology, Cultural | 1 | 2014 | 12 | 0.030 |
Why?
|
| Patient Participation | 2 | 2006 | 94 | 0.030 |
Why?
|
| Hierarchy, Social | 1 | 2014 | 9 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 51 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 8 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 18 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 98 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 129 | 0.030 |
Why?
|
| Computers | 1 | 2013 | 35 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 54 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 158 | 0.020 |
Why?
|
| Tennessee | 1 | 2013 | 93 | 0.020 |
Why?
|
| North Carolina | 1 | 2013 | 127 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 310 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 111 | 0.020 |
Why?
|
| Florida | 1 | 2013 | 478 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 220 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 224 | 0.020 |
Why?
|
| Michigan | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 269 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 678 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 162 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 45 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 1177 | 0.020 |
Why?
|
| Compulsive Personality Disorder | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 179 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2007 | 60 | 0.020 |
Why?
|
| Students | 1 | 2012 | 626 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 2676 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2006 | 317 | 0.020 |
Why?
|
| Informed Consent | 1 | 2006 | 35 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 61 | 0.010 |
Why?
|
| Purines | 1 | 2005 | 40 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 33 | 0.010 |
Why?
|
| Sulfones | 1 | 2005 | 47 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 39 | 0.010 |
Why?
|
| Narration | 1 | 2005 | 37 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 65 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 150 | 0.010 |
Why?
|
| Testosterone | 1 | 2005 | 211 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 6644 | 0.010 |
Why?
|